Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trialJean-Pascal H. Machiels, Ezra E.W. Cohen, Jan B. Vermorken et al.|The Lancet Oncology|2015Cited by 391